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A B S T R A C T
Orally disintegrating tablets (ODTs) manufactured by freeze-drying, also called oral lyophilizates, are a patient-
centred dosage form. They possess ultra-fast disintegration dynamics, have acceptable mechanical strength and
have a smooth mouth texture. In this study, polyvinyl alcohol (PVA) was investigated as an alternative polymeric
binder to gelatin for ODT formulations. A low- and high-dose formulation were in-scope with mannitol as filler
and xanthan gum as a viscosity enhancer. Design of experiments (DoE) methodology was applied to study the
formulation effects on several quality attributes. Sedimentation during the initial phases of freeze-drying was
successfully measured using Raman spectroscopy and could be minimized by adjusting the xanthan gum con-
centration. Multiple linear regression models were subsequently applied to establish design spaces and robust
optimised formulations. A 19 mg hydrochlorothiazide (HCT) as low-dose and 500 mg paracetamol as high-dose
ODT were developed in this study. The work displayed the use of PVA as a viable polymeric binder, and al-
ternative for gelatin, in lyophilized ODTs.
1. Introduction
Orally disintegrating tablets (ODTs) disperse quickly in contact with
saliva before being swallowed. An oral intake is the preferred route of
drug administration as it possesses fewer risks for administration mis-
takes, has a high stability and small packaging size (Hirani et al., 2009;
Velmurugan and Sundar, 2010). ODTs have additional advantages
compared to regular compressed tablets. They are highly convenient, as
they allow intake at any moment without the use of water. They also
avoid the swallowing of big intact tablets or capsules. Moreover, due to
dissolution in the buccal cavity, pre-gastric absorption might even be
possible resulting in a faster onset of action or reduction of early me-
tabolization (Clarke et al., 2003). However, ODTs are still a niche
product in the global tablet market as they have additional require-
ments. As the tablet disintegrates in the mouth, an important issue to
consider in ODTs is the taste perception. Next, ODTs are generally built-
up with more complex formulation systems, to balance between me-
chanical strength and disintegration time. They are also more fragile
than regular tablets requiring feel-off blister systems (Ghosh et al.,
2011; Rao et al., 2008).
Nowadays, commercial manufacturing of ODTs either happens ei-
ther via compression or lyophilization. Compressed ODTs are quite
popular due to the ease and speed of production. However, they require
an intricate formulation design using effervescent excipients to keep the
disintegration time below 30 s. Moreover, they still result in a gritty
mouthfeel since they constitute out of granules (McLaughlin et al.,
2009). On the contrary, freeze-dried ODTs, often called lyophilizates,
have a much shorter disintegration time as they have a very porous
network (Seager, 1998; Ghosh et al., 2011; Rao et al., 2008). Further-
more, disintegration leads to a suspension with a smooth texture that is
easily swallowed or could even coat the oropharyngeal cavity when bio-
adhesive polymers are applied (Jones, 2013).
The main lyophilized ODT technology is the Zydis platform which is
based on batch-wise manufacturing (McLaughlin et al., 2009; Badgujar
and Mundada, 2011). The process starts with the formulation of an
aqueous bulk liquid which is composed of gelatin as polymeric binder
and mannitol as mechanical structure former. The gelatin acts like a
glue to keep all the crystalline particles (i.e. drug substance and fillers)
together in the final ODT, while mannitol adds rigidity ensuring that
the freeze-dried tablet is robust for transport and handling (Seager,
1998). Furthermore, mannitol is highly water-soluble promoting dis-
integration (Omar et al., 2017). Additionally, colorants, pH modifiers,
taste-masking agents, and preservatives can be added if needed. In the
Zydis platform, drug substances are preferably low in dose and water-
insoluble, to limit processing times. Drug substances should also have a
small particle size so that they can be dispersed without the risk of
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sedimentation and to achieve a smooth mouthfeel. In the next process
phase, the bulk liquid formulation is filled into blister pockets and
quickly frozen using a tunnel freezer. Annealing is performed in a
holding chamber and when the whole batch is frozen, all the blisters are
transferred to a large industrial batch freeze-dryer where primary and
secondary drying occurs under vacuum. After drying, the blisters are
sealed airtight and packed (Seager, 1998; Seager, 1999). A consequence
of the semi-continuous freezing mode and batch drying step applied by
Zydis, is the variable annealing time for each blister. This could result in
significant intra-batch pore-size variability and thereupon inconsistent
primary drying times and critical product quality attributes (Kasper and
Friess, 2011). Next, the choice of gelatin as a polymeric binder also
poses some risks. At first, gelatin originates from animal tissue and lacks
consistent quality attributes. The dependency of its viscosity on tem-
perature, pH and time is not constant, leading to inter-batch variability.
A stable viscosity is crucial in the filling stage for accurate dosing and
during loading and early freezing to suppress sedimentation. Moreover,
some parts of the population have ethical constraints to animal-based
products (Murray et al., 2004; Grother, 2000).
Another ODT lyophilization platform is Lyoc. An oil-in-water
emulsion with a large fraction of water-soluble filler (i.e. mannitol or
lactose) is used as a formulation which results in a paste-like con-
sistency that prevents sedimentation. All freeze-drying phases are exe-
cuted in commercial sized freeze-dryers (McLaughlin et al., 2009;
Lafon, 1986). The Lyoc formulation strategy leads to a very low por-
osity and is associated with higher drying times making it less eco-
nomical. Moreover, multiple academic research groups focused on the
development of oral lyophilizates. AlHusban et al. (2010) investigated
the impact of the bloom strength and concentration of gelatin, com-
bining with five different saccharides, on tablet hardness and disin-
tegration time. Inclusion of mannitol lead to elegant tablets and an
optimised 100 μ g clondine HCl tablet was developed. Flórez Borges
et al. (2018) investigated the applicability of PVP as a polymeric binder
while Casian et al. (2017) screened multiple polymeric binders as an
alternative to gelatin and found xanthan gum in a concentration below
1% to form adequate tablets.
It was the objective of this work to investigate the feasibility of
polyvinyl alcohol (PVA) as an alternative polymeric binder to gelatin or
an oil-in-water system. To challenge the proposed PVA formulation
system, a low- and high-dose formulation was evaluated. Mannitol was
considered as the mechanical structure former as it has the ideal
characteristics for lyophilized ODTs. It is reported to shorten disin-
tegration time in a polymeric system and is likely to increase me-
chanical strength due to its crystallization behavior during freeze-
drying (Omar et al., 2017; Izutsu et al., 1994). At last, xanthan gum was
opted as viscosity enhancer in the case PVA would not prevent drug
substance sedimentation during the initial freeze-drying steps. Design
of Experiments and multiple linear regression methodology was in-
scope to achieve optimised but robust formulations.
2. Materials and methods
2.1. Materials
Hydrochlorothiazide (HCT) was used as the poorly water-soluble
low-dose model drug substance and was acquired from Bufa (Ijsselstein,
The Netherlands). Micronized paracetamol from Mallinckrodt (Staines-
upon-Thames, United Kingdom) was used as the poorly water-soluble
high-dose alternative. As excipients, mannitol from ABC Chemicals
(Nazareth, Belgium), polyvinyl alcohol (PVA) 4–88 Emprove (Merck
KGaA, Darmstadt, Germany) with a hydrolyzation grade of 88% and
xanthan gum from ACA Pharma (Waregem, Belgium) were utilized.
2.2. Formulation design
2.2.1. Low-dose formulation
Since the particle size distribution of the initial grade of HCT was
broad (d10: 48.01 μm and d90: 243.47 μm) and rather high for ODTs,
sedimentation of the HCT particles during the loading and freezing
phase was a considerable issue. It was opted to micronize the initial
grade using jet milling. A Grinding System 50 AS Aeroplex Spiral Jet
Mill (Hosokawa Alpine AG, Augsburg, Germany) was utilized to pro-
duce 50 g of micronized grade HCT. The pressure of the injector and
grinding air were set at 4 bar. The feed rate of the initial HCT grade was
1–5 g/min.
The low-dose orally disintegrating tablet formulation was optimized
using design of experiment (DoE) methodology. The concentration of
the drug substance was set to 1.25% (w/w) of the initial bulk for-
mulation. HCT was opted as the low-dose model drug substance as it is
a poorly water-soluble component and it is therapeutically active in a
relatively low dose (i.e. 12.5–50 mg per tablet) (Chapman et al., 2002).
The effect of varying concentrations of PVA, mannitol, and xanthan
gum on the ODT critical quality attributes (CQAs) was investigated.
Disintegration and wetting time was measured to understand the im-
pact of the formulation components on the oral disintegration behavior
of the ODTs. Next, mechanical strength and elastic recovery gave an
idea of the ODT resistance to deformation, essential in the event of
unblistering. At last, the viscosity of the bulk suspension and the re-
lative concentration of the API in the dried ODT were measured to give
insights in the sedimentation behavior of the API during filling and
freezing. Preliminary tests with HCT indicated that a mannitol con-
centration of 4 to 10% (w/w), a PVA concentration between 2.5 and
5.0% (w/w) and a xanthan gum concentration from 0.075 to 0.250%
(w/w) resulted in tablets, adequate to characterize. As intricate effects
and interactions between the formulation factors were expected, a
Central Composite Orthogonal (CCO) design was selected as it evaluates
the factors over five levels. It contains the edge points similar to a full
factorial design but has additional star points extending the experi-
mental domain. A CCO with star distance of 1.353 and resolution of five
was opted resulting in 14 experiments and 3 center point replicates.
Deionized water was used as a suspension medium to bring all for-
mulations ad 100% (w/w).
All formulations were prepared with analytical balances and glass-
ware leading to a factor precision of 0.01% (w/w) for mannitol and
PVA. Xanthan gum was prepared using a dilution strategy, resulting in a
factor precision of 0.005% (w/w).
2.2.2. High-dose formulation
A very similar strategy was followed for the high-dose formulation.
Paracetamol was opted as the model drug substance with the aim to
make an ODT with 500 mg active pharmaceutical ingredient (API). The
size of the tablet was considered in the formulation strategy by adding
the concentration of paracetamol as an additional factor (precision:
0.01% (w/w)) in the DoE study. Maximizing the drug substance con-
centration in the initial bulk suspension would lead to smaller tablets
when considering a fixed dose. Preliminary experiments showed the
manufacturing feasibility of tablets by freeze-drying formulations con-
taining 25 to 33% (w/w) paracetamol, 1 to 2.5% (w/w) mannitol, 1.75
to 4.25% (w/w) PVA and 0.075 to 0.250% (w/w) xanthan gum. A si-
milar CCO design was chosen, leading to 16 edge-, 6 star- and 3 center-
point experiments. The same six quality attributes as described for the
low-dose formulations were also measured for all high-dose experi-
ments.
2.3. Freeze-drying process
Cold-formed aluminium blisters (oPA/Alu/PVC – 25/45/60 μm)
were acquired from IMA (Bologna, Italy). The blister pocket shape
could be approximated by a sliced horizontal cylinder with spherical
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caps with a total length of 40.5 mm, chord length of 23.5 mm and
height of 7.2 mm. Nine tablets per DoE experiment were manufactured
of the low and high-dose formulations by filling 2.5 ml of each bulk
suspension into the blister pockets. The filling operation was executed
at 3 °C to minimize sedimentation of the drug substance.
All formulations were processed together using an Amsco-Finn Aqua
GT4 freeze-dryer (GEA, Köln, Germany). A conservative cycle was
chosen to prevent any defects (i.e. meltback, collapse …). The in-
dividual filled blisters were directly loaded on 3 °C pre-cooled shelves.
Filling all blisters took approximately 30 min. Next, shelves were
brought to −35 °C at a rate of 0.25 °C/min and attained for 30 min at
−35 °C to freeze all samples. Next, a vacuum was induced till 10 Pa
followed by a rise of the shelf temperature (Ts) to−25 °C over 30 min.
Upon convergence of the Pirani and Capacitance pressure sensors,
secondary drying was initiated by raising Ts to 25 °C over 50 min till
completion, monitored by the same pressure sensors.
2.4. Characterization techniques
2.4.1. Drug substance characterization
The particle size distribution of the micronized grades of para-
cetamol and HCT were evaluated using a wet laser diffraction method
(Malvern Mastersizer S, Worcestershire, UK) using a 300RF lens (range
0.05–900 μm). The sample was dispersed in miglyol 812 N (IOI Oleo
GmbH, Witten, Germany) using the MS1 Small Volume Dispersion Unit.
The obscuration of the miglyol suspensions ranged between 10% and
30%. Each measurement was performed in triplicate.
Furthermore, the true density of the micronized drug substances
was determined using a Micrometrics Accupyc 1330 (Norcross, USA).
The device was equilibrated at 25 °C and the sample was 10 times
purged with helium at an equilibration rate of 0.005 psig/min. The
measurement was replicated ten times. The true density was de-
termined by dividing the true volume by the sample weight.
2.4.2. Disintegration time
The oral lyophilizates method described in EDQM (2005) was op-
timized by using a water-soluble dye to increase the contrast between
wetted and unwetted tablet fragments. A 5 cm petridish was filled with
15 ml 0.1% (m/V) congo red dye solution (Sigma, Saint-Louis, USA)
and agitated by a 15 mm stir bar at 200 rpm. Time till full disintegra-
tion (DT [s]) was recorded in duplicate using a stopwatch.
2.4.3. Wetting time
The wetting time (WT [s]) was measured by timing the complete
absorption of 5 mL 0.1% (m/V) congo red dye solution by the tablet
from a 5 cm petri dish with a glass fiber filter (diameter: 47 mm,
thickness: 1.5 mm) (Satorius GmbH, Göttingen, Germany). Tablets were
carefully placed on a complete saturated filter while having no direct
contact with the excess of dye solution. The experiments were done in
duplicate.
2.4.4. Mechanical strength
An indentation test similar to Vanbillemont et al. (2020) was per-
formed to measure the mechanical strength and elastic recovery. The
mechanical strength (MS [Pa]) was calculated according Eq. (1) from
the load (F [N]) resulting after 650 μ m of indentation (h [m]) with a
1.5 mm steel ball (Dind [m]) at 100 μ m/s. Elastic recovery (ER [%]) was
computed by the division of the area of the unloading by the loading
curve.
=MS F
πD hind (1)
2.4.5. Sedimentation
The first step to characterize and understand the extent of drug
substance particle sedimentation during the initial phases of freeze-
drying (i.e. blister filling and freezing) was measuring the viscosity of
the bulk solution at freeze-dryer loading conditions. Approximately
1.6 ml of the bulk suspension was loaded on a 60 mm parallel geometry
plate at 3 °C using a Haake Mars III rheometer (Thermo Scientific, MA,
USA). A gap of 140 μ m was set and the excess of suspension was re-
moved. The rotational mode was used to measure the viscosity (η
[Pa.s]) in function of the shear rate (γ [1/s]) by applying ten levels of
rotational speed leading to shear rates approximately ranging from
1000 to 10−4 1/s. Prior to the measurements, samples were equili-
brated at the measuring gap and 3 °C during 180 s. Next, the viscosity
was measured after 60 s of enduring each share rate level. At last, a
power fluid law ( = −η Kγn 1) was fitted to find the apparent viscosity at
a low shear rate of 10−3 1/s with K the flow consistency index [Pa.s2]
and n the flow behavior index [–].
The second step was to quantify the extent of sedimentation in the
freeze-dried tablets. The relative concentration of the drug substance at
the bottom versus the top of the ODT was measured using Raman
spectroscopy. A Raman RXN2 analyzer with Phat probe from Kaiser
Optical Systems (Ann Harbor, MI, USA) was used to obtain a spectrum
of the top and bottom of the tablet. Identical acquisition settings, 15
scans at probe-sample distance of 250 mm resulting in a measuring spot
size of 6 mm, were used for all measurements. A baseline correction
was applied using the standard normal variate (SNV) pre-processing
function in PLS-Toolbox (Eigenvector Research, Manson, WA, USA). As
only the drug substance concentration near the surface was measured
using the Phat probe, the degree of sedimentation (Sed [–]) could be
quantified as the difference in peak area of the bottom (Abottom) versus
the top (Atop) compared to the pure drug substance (ADS)
( = −Sed A A A( )/bottom top DS). A sedimentation degree of 1 would mean
that the bottom of the tablet only consists out of drug substance while
the top of the tablet would contain no drug substance, whereas 0 would
indicate similar concentrations at the tablet top and bottom. The sedi-
mentation degree was calculated by the average result of four peaks for
HCT (1598, 1155, 710 and 265 cm−1) and two for paracetamol (857
and 797 cm−1) assigned to the respective drug substances.
2.5. Multiple linear regression
The DoE was constructed and evaluated in Modde Pro 12.1
(Sartorium Stedim Biotech, Umeå, Sweden) software. An individual
multiple linear regression (MLR) model was developed for each re-
sponse (i.e. the ODT quality attributes) to establish an empirical re-
lationship with the induced variation in the factors (i.e. the con-
centration of excipients). Since a CCO experimental design was chosen,
factors were evaluated at five different levels enabling the use of
quadratic interaction models according to the structure displayed in Eq.
(2).
̂ ̂ ̂ ̂ ̂ ̂ ̂
̂ ̂ ̂
= + + + + + + …
+ + +
− − −
y β β x β x β x β x β x x
β x β x β i x x
( )
( )j i j i j i i
0 1 1 2 1
2
3 2 4 2
2
5 1 2
2 1
2
1 (2)
Where ̂y is the predicted response value; i is the amount of factors, j
is the amount of model terms, x1 to xi the different factor values; β0 the
intercept; β β,1 3 and −βj 2 the coefficients of the single factors; β β,2 4 and
−
βj 1 the coefficients of the quadratic factors and β β, j5 the coefficients of
the interaction terms.
All factors were scaled and centered, which makes the regression
coefficients for the different factors comparable. The coefficients from
each MLR model were calculated with Modde software and displayed in
the result section with their 95% confidence interval. The magnitude of
the coefficient gives an idea of the importance of that model term in the
estimation of the response.
The Modde optimizer function was also applied to construct a de-
sign space and select the most robust formulation resulting into the
desired ODT CQAs (see in more detail below). At last, the selected
optimal formulation was verified by analogous freeze-drying and
B. Vanbillemont and T. De Beer International Journal of Pharmaceutics 588 (2020) 119717
3
characterization of the resultant tablets.
3. Results and discussion
The aim of this work was to develop a lyophilized ODT low-dose,
containing hydrochlorothiazide, and a high-dose paracetamol for-
mulation based on PVA as an alternative polymeric binder. Mannitol
and xanthan gum were used as additional excipients. Mannitol acted as
a crystalline bulking agent to give the tablets an elegant structure and
sufficient mechanical properties. Xanthan gum was investigated as a
viscosity enhancer to minimize sedimentation during the initial phases
of freeze-drying. In the first phase of the project, a DoE was constructed
for both the low- and high-dose ODTs to investigate the formulation
effects on the CQAs and the necessity of all constituents of the for-
mulation. In a second project phase, the optimized MLR models re-
sulting from the DOEs were used to optimize the formulations. Design
spaces were constructed to determine a robust low-dose and high-dose
formulation which was subsequently experimentally verified. In the
next project phase, essential freeze-drying parameters were determined
from the robust optimized formulations and blister-freeze-dryer system
to enable an optimal process comparison. At last, an optimization of the
primary drying stage was proposed for each optimized formulation to
reduce processing times.
3.1. Low-dose hydrochlorothiazide formulation
3.1.1. Preliminary tests
Preliminary tests with HCT showed problematic sedimentation be-
tween filling the blisters and full solidification of the formulation.
Therefore, it was opted to micronize the initial HCT grade using jet
milling reducing the particle size from a median diameter of 119.96 μm
to 24.47 μm. Other parameters influencing the sedimentation are the
true density of HCT (i.e. 1.6968 g/ml), bulk density, and viscosity of the
bulk formulation. Xanthan gum was added as a natural viscosity en-
hancer to reduce the risk of sedimentation. However, its concentration
should be appropriate as it could delay the ODT disintegration time.
Corveleyn and Remon (1997) found an upper limit of 0.5% (w/V) in a
maltodextrin system. Preliminary tests revealed a maximal xanthan
gum concentration of 0.25% (w/w) in the PVA based system under
evaluation. Xanthan gum concentration under 0.075% (w/w) displayed
visible sedimentation during the bulk preparation. Moreover, the filling
and loading operation was executed at 3 °sC to maximize the viscosity
of the bulk suspension. Bulk suspensions with a mannitol concentration
between 4 and 10% (w/w) and PVA concentration between 2.5 and 5%
(w/w) resulted in ODTs which had mechanical properties suitable to
characterize. Higher PVA concentrations seemed to severely restrict
disintegration and higher mannitol concentrations would yield even
higher dried product resistances lengthening freeze-drying processing
times.
3.1.2. Evaluation of the low-dose DoE
The disintegration time of all tablets in the DoE ranged between 2
and 10 s (cfr. Table 1), which is well below the FDA-limit of 30 s (CDER,
2008) and appropriate for lyophilized ODTs. However, the test was not
very discriminative between the different ODTs as the differences were
close to the resolution of the method (1 s). As a result, all the for-
mulation factor effects in the DoE seemed to be insignificant upon
disintegration time. Alternative disintegration time determination
techniques with higher precision might give more detailed insights. For
example, Abdelbary et al. (2005) describes a DT method utilizing a
texture analyzer mimicking the forces occurring in the buccal cavity.
Nonetheless, the wetting time test appeared to be a valuable alter-
native. Increasing the PVA from 1.75 to 4.25% (w/w) and xanthan gum
from 0.075 to 0.250% (w/w) resulted in an undesirable effect on WT of
+8.1 ± 2.2 s and +3.1 ± 2.2 s, respectively. However, the PVA effect
on WT stabilized with higher concentrations evidenced by the
significance of a negative PVA2 (−4.2 ± 2.8 s). By contrast, increasing
the fraction of mannitol decreased the WT (−4.1 ± 2.2 s). These ob-
servations are in agreement with literature as mannitol, a highly soluble
sugar alcohol, is reported to enhance the solubility of tablets with
polymer systems (Tajarobi et al., 2009).
The mechanical strength by indentation showed a clear effect of the
formulation parameters with values varying between 0.11 to 0.76 MPa.
These values are very comparable to some commercialized products
(i.e. Risperdal Quicklet: 0.12 MPa and Feldene Melt: 0.80 MPa) as re-
ported by Vanbillemont et al., 2020. All the excipients contributed to
the mechanical strength of the tablet with mannitol as the main con-
tributor (+0.36 ± 0.02 MPa), followed by PVA (+0.19 ± 0.02 MPa)
and xanthan gum (+0.07 ± 0.02 MPa). Interactions of mannitol with
the other excipients also added strength to the ODTs (PVA×mannitol:
+0.10 ± 0.03 MPa and mannitol×xanthan: +0.04 ± 0.03 MPa). The
indentation test was also capable of characterizing the elastic recovery
(ER). ODTs with a high ER are preferential as they can resist more force
before fracturing or permanent deformation during unblistering of the
tablet. The HCT tablets showed a variation in ER from 14.22 till 31.34%
which is on average higher than the commercial ODTs measured by
Vanbillemont et al., 2020 (i.e. Risperdal Quicklet: 6.57% to Paralyoc:
18.22%). However, only a portion of the observed variation could be
attributed to formulation effects. PVA had a beneficial effect of +6.13
± 3.77% which is reasonable as most polymers have elastic character-
istics, the other effects had large uncertainties leading to their (near)
insignificance.
At last, the sedimentation of HCT particles was investigated and
proved to be an important factor to take into account. Sedimentation
(Sed) measured by Raman spectroscopy varied between an
accepTable 0.023 and a problematic 0.69. The viscosity at a shear rate
of 10−3 1/s varied between 0.86 and 224.86 Pa.s. Both responses had to
be log-transformed to normalize the data enabling multiple linear re-
gression. It appeared that only xanthan gum was responsible for the
significant reduction in Sed (−0.77 ± 0.26 log(%)) and increase in
viscosity with a xanthan effect of 1.89 ± 0.16 log(Pa.s) and xanthan2 of
−0.27± 0.22 log(Pa.s). It is clear that xanthan gum works properly as a
viscosity enhancer in the applied concentration range and was neces-
sary in the HCT formulation as it nearly completely inhibits sedi-
mentation at its higher levels.
3.2. High-dose paracetamol formulation
3.2.1. Preliminary tests
The main difficulty encountered in the preliminary tests of the high-
dose formulation was the associated viscosity raise with a higher
paracetamol content. Formulations containing more than 33% (w/w)
paracetamol had a considerably high viscosity somewhat impeding the
filling process. Formulations with more than 35% (w/w) had a paste-
like texture which made volumetric filling with a pipette nearly im-
possible. The star point of the CCO design with the highest paracetamol
content (i.e. experiment HD18) was for these reasons lowered to 35%
(w/w). A lower paracetamol limit of 25% (w/w) was chosen since a
500 mg tablet was in-scope and ODTs of approximately 2 ml were
considered the absolute limit. A higher paracetamol concentration was
desirable as it would lead to a smaller ODT volume for a similar dose.
Slightly lower PVA and substantially lower mannitol concentrations,
compared to the low-dose HCT formulations, were sufficient to achieve
appropriate tablets by freeze-drying. A PVA concentration between
1.75 and 4.25% (w/w) appeared enough to produce ODTs with a decent
structural integrity. Furthermore, only a mannitol concentration be-
tween 1 and 2.5% (w/w) was necessary to produce elegant and strong
tablets. The high solid content of paracetamol (i.e. 25 to 33% (w/w))
contributed also to the structural integrity of the ODTs.
Characterization of the micronized paracetamol grade resulted in a
median particle diameter of 6.43 μ m and true density of 1.1998 g/ml.
Micronized paracetamol particles are significantly smaller and less
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dense compared to HCT particles. When considering the stokes law for
sedimentation, HCT would develop a sedimentation speed 8.5-fold
higher than paracetamol particles. Moreover, due to the higher particle
content in the high-dose formulation, there would also be more parti-
cle–particle interactions slowing down sedimentation. For the reasons
outlined above, sedimentation was expected to be less of a concern in
this high-dose formulation. However, as the sedimentation in the high-
dose formulation was hard to observe by visual inspection in the pre-
liminary experiments, a similar xanthan gum range as was applied as in
the low-dose experiments (0.075 till 0.25% (w/w)) was deemed ap-
propriate.
3.2.2. Evaluation of the high-dose DoE
The high-dose tablets showed a similar variation (3 to 12 s) in
disintegration time compared to the HCT ODTs (cfr. Table 2). But
contrary to HCT, the variation could partially be contributed to for-
mulation effects. Both PVA (PVA2: +2.1 ± 2.0 s) and xanthan gum
(+3.9 ± 1.5 s) slowed down the disintegration time. This effect was
already reported in the literature as polymers tend to gel upon hydra-
tion slowing down the penetration of the solvent (Corveleyn and
Remon, 1997). The wetting times observed for the high-dose ODTs
seemed less discriminatory. Significant effects were less than 1 s, which
is the resolution of the method, and were deemed irrelevant. It is re-
markable that an opposite observation was made in the discriminatory
power of the disintegration and wetting time test in the high-dose
Table 1
Central Composite Orthogonal design for the low-dose hydrochlorothiazide formulation with results of all characterization techniques applied on the bulk suspension
and resultant ODTs. All concentrations are expressed as a mass percentage of the initial bulk suspension. Man stands for mannitol and XG for xanthan gum
Name PVA Man XG DT WT MS ER η Sed
[% w/w] [% w/w] [% w/w] [s] [s] [MPa] [%] [Pa.s] [–]
LD1 2.50 4.00 0.075 3 9 0.13 22.24 1.38 0.40
LD2 5.00 4.00 0.075 3 20 0.22 31.34 0.86 0.69
LD3 2.50 10.00 0.075 6 8 0.38 18.83 2.42 0.60
LD4 5.00 10.00 0.075 6 18 0.62 27.98 0.95 0.320
LD5 2.50 4.00 0.250 2 16 0.16 19.26 107.03 0.096
LD6 5.00 4.00 0.250 10 23 0.24 21.25 111.17 0.063
LD7 2.50 10.00 0.250 5 8 0.43 15.36 145.12 0.037
LD8 5.00 10.00 0.250 7 18 0.76 19.70 127.4 0.023
LD9 2.06 7.00 0.163 2 9 0.22 14.22 19.25 0.065
LD10 5.44 7.00 0.163 6 16 0.48 22.49 19.46 0.068
LD11 3.75 2.94 0.163 10 20 0.11 25.91 21.80 0.079
LD12 3.75 11.06 0.163 4 14 0.59 20.46 21.30 0.057
LD13 3.75 7.00 0.044 4 14 0.32 19.47 1.15 0.22
LD14 3.75 7.00 0.281 4 20 0.43 19.39 224.86 0.027
LD15 3.75 7.00 0.163 4 16 0.37 23.15 23.53 0.13
LD16 3.75 7.00 0.163 4 16 0.38 17.25 24.19 0.11
LD17 3.75 7.00 0.163 6 17 0.38 16.59 24.53 0.083
Table 2
Central Composite Orthogonal design for the high-dose paracetamol formulation with results of all characterization techniques applied on the bulk suspension and
resultant ODTs. All concentrations are expressed as a mass percentage of the initial bulk suspension. APAP stands for paracetamol, Man for mannitol and XG for
xanthan gum
Name APAP PVA Man XG DT WT MS ER η Sed
(% w/w) (% w/w) (% w/w) (% w/w) [s] [s] [MPa] [%] [Pa.s] [–]
HD1 25.00 1.75 1.00 0.075 3 10 0.77 23.87 4.86 −8.2 × 10−5
HD2 33.00 1.75 1.00 0.075 4 12 1.58 27.17 13.00 3.6 × 10−3
HD3 25.00 4.25 1.00 0.075 6 6 1.39 26.12 14.31 3.1 × 10−3
HD4 33.00 4.25 1.00 0.075 6 14 2.26 30.75 28.64 3.7 × 10−3
HD5 25.00 1.75 2.50 0.075 5 10 1.04 22.14 7.12 0.033
HD6 33.00 1.75 2.50 0.075 4 11 2.05 26.71 12.35 7.3 × 10−3
HD7 25.00 4.25 2.50 0.075 4 12 1.67 35.17 16.79 −5.2 × 10−3
HD8 33.00 4.25 2.50 0.075 4 6 3.53 33.18 35.76 4.9 × 10−4
HD9 25.00 1.75 1.00 0.250 5 9 0.82 14.07 417.12 −3.9 × 10−4
HD10 33.00 1.75 1.00 0.250 10 9 1.49 21.57 625.07 9.5 × 10−3
HD11 25.00 4.25 1.00 0.250 9 13 1.30 28.17 322.25 1.4 × 10−3
HD12 33.00 4.25 1.00 0.250 10 9 2.62 26.40 663.12 0.011
HD13 25.00 1.75 2.50 0.250 6 18 0.95 16.13 328.70 4.9 × 10−3
HD14 33.00 1.75 2.50 0.250 8 14 1.92 20.73 631.98 8.2 × 10−3
HD15 25.00 4.25 2.50 0.250 12 14 1.80 24.26 767.45 0.011
HD16 33.00 4.25 2.50 0.250 9 14 2.60 27.95 519.75 0.020
HD17 22.81 3.00 1.75 0.163 4 12 0.82 26.97 114.47 6.1 × 10−3
HD18 35.00 3.00 1.75 0.163 8 15 2.31 29.58 193.82 1.4 × 10−3
HD19 29.00 1.07 1.75 0.163 10 12 1.09 17.10 117.34 4.3 × 10−3
HD20 29.00 4.93 1.75 0.163 10 16 2.31 32.67 257.31 5.8 × 10−4
HD21 29.00 3.00 0.59 0.163 8 7 2.31 32.67 205.45 0.011
HD22 29.00 3.00 2.91 0.163 6 15 2.31 32.67 128.28 2.7 × 10−3
HD23 29.00 3.00 1.75 0.027 3 8 1.94 21.33 7.70 −5.1 × 10−3
HD24 29.00 3.00 1.75 0.298 8 12 1.80 16.54 1131.08 7.3 × 10−3
HD25 29.00 3.00 1.75 0.163 9 11 1.80 26.29 402.26 0.017
HD26 29.00 3.00 1.75 0.163 5 9 1.76 25.33 118.30 7.2 × 10−3
HD27 29.00 3.00 1.75 0.163 7 10 1.87 20.09 213.55 9.8 × 10−4
B. Vanbillemont and T. De Beer International Journal of Pharmaceutics 588 (2020) 119717
5
versus the low-dose ODTs. However, as these times were relatively
short they were hard to measure in high resolution with the applied
methods which resulted in quite extensive errors on the significant ef-
fects. It has to be noted, that this is not necessarily problematic as all
measurements were short compared to the FDA limit (30 s).
Vanbillemont et al., 2020 proposed the digital imaging of the disin-
tegration and wetting test, which makes the endpoint determination of
both tests less subjective and results in data with higher time resolution.
It would be advisable to apply these methods if more detailed relations
between formulation components on sub-10 s disintegration times
would be required. Furthermore, an assessment in a bio-relevant
medium such as simulated saliva could have more predictive power
towards the in vivo situation (Ali et al., 2019).
The mechanical strength of the paracetamol tablets, ranging from
0.77 till 2.62 MPa, was considerably higher than the HCT tablets. The
stronger paracetamol tablets came close to values measured for ODTs
marketed in push-through blisters, i.e. Paralyoc: 3.23 MPa
(Vanbillemont et al., 2020). Similar to HCT, all excipients contribute to
the mechanical strength. The paracetamol content was the biggest
contributor with an effect of +1.02 ± 0.21 MPa, followed by PVA
(+0.81 ± 0.21 MPa) and mannitol (+0.32 ± 0.21 MPa). Minor quad-
ratic effects were also observed; mannitol2 −0.32 ± 0.28 MPa and
paracetamol2−0.31± 0.28 MPa. Elastic recovery values comparable to
the HCT ODTs were observed, ranging between 14.07 and 35.17%. PVA
resulted likewise in the biggest effect (+8.05 ± 2.60%). Nonetheless,
the observed ER variation could be explained in more detail compared
to the HCT ODTs. Paracetamol also contributed beneficially (+2.75 ±
2.60%), whereas mannitol showed a minimum around the center-points
(mannitol2: +5.75 ± 3.51%). Contrarily, xanthan gum had an adverse
effect (xanthan:−5.12 ± 2.60%; xanthan2:−5.73 ± 3.51%). From this
data, it appears that the plasto-elastic properties of an ODT formulation
is an intricate interaction between all excipients but that also ex-
emplifies the appropriate functionality of PVA in an ODT formulation.
When investigating the sedimentation data using Raman spectro-
scopy, it was concluded that no sedimentation was observed. Moreover,
the repeated center point experiments showed a similar variation in
sedimentation then the variation observed from changing the for-
mulation factors. Nonetheless, a clear spread of the viscosity at a shear
rate of 10−3 1/s was noticeable with numbers ranging from 4.86 to
1131.08 Pa.s. This data-set had to be logarithmically transformed to
allow MLR modeling. As expected, xanthan gum was a very outspoken
contributor (+1.53 ± 0.15 log(Pa.s)). Next, PVA and paracetamol were
minor contributors to the viscosity: +0.23 ± 0.15 log(Pa.s) and +0.22
± 0.15 log(Pa.s) respectively. Moreover, significant shear thinning of all
suspensions was observed. As such, the suspensions developed a higher
viscosity during the stagnant loading and freezing phase while having a
lower viscosity during an agitated state. This is beneficial to the pro-
cessability as sedimentation is diminished at the high-risk process
phases while the filling could be optimized by agitation of the sus-
pension.
3.3. Formulation optimization
3.3.1. Low-dose formulation
All MLR-models were improved by removing its non-significant
factors, interaction and quadratic terms, thereby increasing the model
predictability (Q2 [–]) (cfr. Fig. 1). In the case of the low-dose DoE all
responses could be described adequately, i.e. a high goodness of fit (R2
[–]), Q2, model validity, and repeatability; except for disintegration
time (DT). The model validity of η was low due to an excellent re-
peatability of the center-point replicates. Model validity uses that re-
plicate error to compare it to the lack-of-fit of the model. This approach
is not completely valid if extremely low replicate errors are observed
which was the case for η due to the logarithmic transformation. DT is a
quite essential parameter for ODTs. It should be below 30 s according to
FDA guidelines (CDER, 2008) and there is a 3 min Ph.Eur. limit (EDQM,
2014). As all tablets resulting from the investigated experimental space
was below both limits, this was not a concern. Nonetheless, in regard to
the patient experience, a low as possible DT was preferred. Since the
MLR-model for DT was inadequate to use (R2 and Q2 below 0.3), it was
opted to use wetting time (WT) as a surrogate descriptor. WT could be
modeled well and also describes the solvent penetration, ultimately
softening the tablet ready to be swallowed.
The aim was to develop an ODT that was similar or even more
qualitative than the top-performing commercial ODTs. Therefore, the
acceptance criteria for each response in the optimization exercise was
based on the low-dose commercial ODTs properties determined in
Vanbillemont et al., 2020. As no sedimentation or viscosity data was
acquired for these commercial ODTs and due to the fact that sedi-
mentation should be minimized as much as possible, only the Sedmodel
was included in the Modde optimizer with a maximum limit of 0.070.
For the wetting time, a maximum of 16 s was opted. As both mechanical
strength and elastic recovery should be maximized, only minimum
limits were set at respectively 0.42 MPa and 15.0% (cfr. Table 3).
Next, contour plots were constructed for the four relevant low-dose
formulation ODT responses to be optimized (i.e.WT MS ER, , and Sed)
with the higher described optimized MLR-models and overlaid with
their respective acceptance limits to obtain a sweet-spot plot (cfr.
Fig. 2). A sweet-spot, satisfying all four criteria, could be achieved and
is depicted as the bright green area. The mannitol concentration had to
be maximized to allow strong enough tablets (i.e. MS-limit) and to
decrease the wetting time of the tablet. Next, xanthan gum had to be at
a sufficiently high level (< 0.18% (w/w)) to decrease sedimentation
behavior. At last, a balance in the PVA concentration (3 to 4% (w/w))
was necessary to obtain tablets with sufficient strength and elasticity
but without lengthen the wetting time to much.
Furthermore, a design space was constructed since the selection of a
robust formulation was desired (cfr. Fig. 3). The design space takes into
account the precision of the factors and the uncertainty of the MLR-
model predictions to calculate the probability of failure for each com-
bination of excipients. A limit of 1% failure was set as acceptable. The
optimizer function of Modde Pro 12.1 explored the design space for the
most robust formulation combination resulting in a low-dose formula-
tion with 1.25% (w/w) HCT, 2.96% (w/w) PVA, 9.98% (w/w) mannitol
and 0.250% (w/w) xanthan gum and a probability of failure of 0.47%.
The design space has a rather small area with compliant characteristics.
However, the area could considerably be enlarged if the HCT particle
size would be decreased even further. Smaller particle size could sig-
nificantly reduce sedimentation which was a major limiting condition
of the sweet plot (cfr. Fig. 2).
Ultimately, the optimal low-dose ODT formulation was experi-
mentally verified and produced through freeze-drying several tablets
using the protocol specified above. The MLR model predicted quality
attributes of this optimized ODT was also compared to the experi-
mentally measured values. The experimental values are reported next
to the 95% confidence interval (CI) of the MLR-models. For disin-
tegration time, wetting time and sedimentation the values were ac-
ceptable and within the CI (DT: 4 s [2.9 to 5.0 s]; WT: 13 s [9.5 to 14.1
s] and Sed: 0.030 [0.027 to 0.053]). However, the mechanical strength
was slightly lower than predicted but still acceptable (MS: 0.42 MPa
[0.44 to 0.57 MPa]) and the elastic recovery was just below the 15%
lower limit (ER: 14.05% [15.01 to 17.53%]). However, it was opted to
advance with this robust formulation as the quality attributes were still
comparable to the commercial low-dose ODTs characterized in
Vanbillemont et al. (2020).
3.3.2. High-dose formulation
An analogous approach was taken for the optimization of the high-
dose paracetamol formulation. The MLR models from all responses
except Sed and viscosity were used for the optimization exercise, as no
risk of sedimentation was perceived. The envisaged high-dose ODT
quality attribute acceptance limits were set stricter for mechanical
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strength and elastic recovery compared to the low-dose HCT ODT as the
aim was to make a comparable or superior ODT then the commercial
Paralyoc ODT (Vanbillemont et al., 2020). The maximum limit for
disintegration time was kept at 7 s and for wetting time at 16 s. The
mechanical strength lower limit was raised to 2 MPa and the elastic
recovery minimum to 20%. Employing the MLR-models and these ac-
ceptance limits, a sweet-spot plot was constructed to find the area of
acceptance (cfr. Fig. 4). The sweet spot plot indicated that the xanthan
gum concentration should be minimized to ensure sufficient elastic
recovery and an acceptable disintegration time. Furthermore,
increasing the paracetamol and mannitol concentration resulted in
stronger and faster disintegrating tablets. At last, the PVA concentration
should be balanced to achieve the most appropriate formulation. Con-
trarily, the wetting time was acceptable with all formulation combi-
nations.
The ambition was to develop an as small as possible high-dose ODT.
Maximizing the drug substance concentration would consequently re-
sult in a smaller dimension when keeping the dose constant. The DoE
indicated that higher paracetamol concentrations were even beneficial
for the tablet quality, but 33% (w/w) was considered the upper limit as
the viscosity would hamper accurate dosing at higher concentrations.
Furthermore, xanthan gum at the lowest level was sufficient to counter
any sedimentation. Herewith, a design space was constructed (cfr.
Fig. 3 and a robust area was indeed found at 33% (w/w) paracetamol
and 0.075% (w/w) xanthan gum. Both values were used as fixed inputs
in the optimizer function. Modde found the most robust formulation at
a balance between PVA and mannitol of respectively 3.39% (w/w) and
2.76% (w/w). This combination was associated with a 0.06% prob-
ability of failure. Upon comparing the design space of the low- and
high-dose formulation, it is clear that there is much more room for
Fig. 1. Model descriptors for the MLR used in the formulation optimization exercise. (left) descriptors for the low-dose HCT formulation; (right) descriptors for the
high-dose paracetamol formulation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 3
optimization acceptance criteria of the ODT critical quality attributes for the
low and high dose formulation.
Response Low-dose High-dose
DT [s] – <7
WT [s] <16 <16
MS [MPa] >0.42 >2.00
ER [%] >15.0 >20.0
Sed [–] <0.070 –
Fig. 2. 3-D Sweet spot plot for the low-dose HCT formulation. Conditions that meet all criteria are colored bright green. The black lines depict the corresponding
acceptance limits. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 3. Design spaces for (left) the low-dose 1.25% HCT (w/w) formulation at 10% (w/w) mannitol and (right) the high-dose paracetamol (33% w/w) formulation at
0.075% (w/w) xanthan gum (XG). The color scale represents the probability of failure in percentage and the shading represents experimental area outside the corner
points but still inside the star points of the DoE. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
Fig. 4. 4-D Sweet spot plot for the high-dose paracetamol formulations. Conditions that meet all criteria are colored bright green. The black lines depict the
corresponding limits. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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process adaptations or unexpected disturbances, i.e. incoming material
variability, in the case of the high-dose ODTs since the design space (i.e.
green area) was significantly larger (cfr Fig. 3).
The robust high-dose formulation containing 33% (w/w) para-
cetamol, 3.39% (w/w) PVA, 2.76% (w/w) mannitol and 0.075% (w/w)
xanthan gum was also experimentally verified by formulating the bulk
suspension, producing the ODT (cfr. Fig. 5) and measuring its quality
attributes DT WT MS, , and ER of the freeze-dried tablets. All model
predictions were accurate as the experimentally verified quality attri-
butes fell inside the 95% CI of the predicted quality attributes (DT: 6 s
[3.2 to 6.1 s]; WT: 8 s [7.5 to 12.8 s]; MS: 3.01 MPa [2.52 to 3.01 MPa]
and ER: 30.46% [30.34 to 36.57%].
4. Conclusion and future perspectives
An alternative for the current lyophilized ODT formulation strate-
gies was investigated and was found to be suitable for both a low- and
high-dose tablet. A combination of PVA as a polymeric binder, mannitol
as structure former, and xanthan gum as viscosity enhancer was suc-
cessfully optimized for a hydrochlorothiazide and paracetamol ODT
using DoE methodology. The particle size of HCT was the main lim-
itation encountered in the low-dose HCT formulation. However, the
resultant sedimentation was successfully measured using Raman spec-
troscopy, and setting xanthan gum at a level of 0.25% (w/w) severely
limited this sedimentation. In the case of the high-dose formulation,
bulk suspensions containing 33% (w/w) paracetamol proved to be
manufacturable while yielding excellent tablet quality attributes. This
drug substance concentration enables the production of high-dose
lyophilized ODTs up to 500 mg.
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